Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
暂无分享,去创建一个
[1] J. Weitz,et al. The mechanism of action of thrombin inhibitors. , 2000, The Journal of invasive cardiology.
[2] V. Fuster,et al. Guide to Anticoagulant Therapy: Heparin: A Statement for Healthcare Professionals From the American Heart Association , 2001, Circulation.
[3] R. Collins,et al. Randomized, Double-blind Comparison of Hirulog Versus Heparin in Patients Receiving Streptokinase and Aspirin for Acute Myocardial Infarction (HERO) , 1997 .
[4] V. Fuster,et al. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. , 1994, Circulation.
[5] J. Maraganore,et al. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. , 1990, Biochemistry.
[6] M. Simoons. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. , 1996, The New England journal of medicine.
[7] J. W. Schaeffer,et al. ACC/AHA guidelines for the management of patients with unstable angina and non–st-segment elevation myocardial infarction: A report of the american college of cardiology/ american heart association task force on practice guidelines (committee on the management of patients with unstable angina) , 2000 .
[8] Carl J Pepine,et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.
[9] W. Hoyt,et al. Letter: Suprastriate hemianopia. , 1974, Lancet.
[10] J. Cairns,et al. Antithrombotic agents in coronary artery disease. , 1989, Chest.
[11] C. Cannon,et al. Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial. , 1995, Circulation.
[12] P. Théroux,et al. Aspirin, heparin, or both to treat acute unstable angina. , 1988, The New England journal of medicine.
[13] E. Antman. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. , 1996, Circulation.
[14] H. White. Direct thrombin inhibition and thrombolytic therapy: rationale for the Hirulog and Early Reperfusion/Occlusion (HERO-2) trial. , 1998, The American journal of cardiology.
[15] A. Telford,et al. TRIAL OF HEPARIN VERSUS ATENOLOL IN PREVENTION OF MYOCARDIAL INFARCTION IN INTERMEDIATE CORONARY SYNDROME , 1981, The Lancet.
[16] J. Maraganore,et al. Kinetic mechanism for the interaction of Hirulog with thrombin. , 1994, Biochemistry.
[17] V. Hasselblad,et al. Clinical outcomes of bivalirudin for ischemic heart disease. , 1999, Circulation.
[18] E. Braunwald,et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. , 1993, The American journal of cardiology.
[19] J. Maraganore,et al. Anticoagulant Activity of Hirulog™, a Direct Thrombin Inhibitor, in Humans , 1993, Thrombosis and Haemostasis.
[20] B. Chaitman,et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.
[21] M. Whooley,et al. Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients With Unstable Angina: A Meta-analysis , 1996 .
[22] A. Mattioli,et al. Organization to Assess Strategies for Ischemic Syndrome (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on preventing death, myocardial infarction, refractory angina and revascularization procedures in patients with acute myocardial ischemia without ST eleva , 1999 .
[23] J. Weitz. Low-molecular-weight heparins. , 1997, The New England journal of medicine.